Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - HC Wainwright lifted their FY2024 earnings per share (EPS) estimates for shares of Tenaya Therapeutics in a report issued on Thursday, November 7th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($1.35) for the year, up from their previous estimate of ($1.46). HC Wainwright has a "Buy" rating and a $18.00 price objective on the stock. The consensus estimate for Tenaya Therapeutics' current full-year earnings is ($1.40) per share. HC Wainwright also issued estimates for Tenaya Therapeutics' Q4 2024 earnings at ($0.31) EPS, FY2025 earnings at ($1.34) EPS, FY2026 earnings at ($1.35) EPS, FY2027 earnings at ($1.07) EPS and FY2028 earnings at ($0.64) EPS.
Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.07.
Several other equities research analysts have also recently issued reports on the stock. Canaccord Genuity Group restated a "buy" rating and issued a $16.00 target price on shares of Tenaya Therapeutics in a report on Friday, October 18th. Chardan Capital lowered their price target on Tenaya Therapeutics from $20.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday. Leerink Partners reaffirmed an "outperform" rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Finally, Piper Sandler reiterated an "overweight" rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $14.75.
Get Our Latest Stock Report on Tenaya Therapeutics
Shares of NASDAQ TNYA opened at $2.76 on Monday. The firm's 50-day moving average price is $2.05 and its 200-day moving average price is $3.02. Tenaya Therapeutics has a 52-week low of $1.61 and a 52-week high of $7.01. The company has a market cap of $217.74 million, a PE ratio of -1.92 and a beta of 2.34.
In related news, CEO Faraz Ali sold 9,748 shares of the firm's stock in a transaction on Friday, August 16th. The stock was sold at an average price of $2.89, for a total value of $28,171.72. Following the transaction, the chief executive officer now directly owns 188,331 shares of the company's stock, valued at approximately $544,276.59. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 19,539 shares of company stock worth $56,468 in the last 90 days. 32.76% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new position in Tenaya Therapeutics during the third quarter valued at approximately $49,000. The Manufacturers Life Insurance Company increased its stake in shares of Tenaya Therapeutics by 43.2% in the second quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company's stock worth $72,000 after purchasing an additional 7,000 shares in the last quarter. Algert Global LLC bought a new stake in shares of Tenaya Therapeutics during the 2nd quarter valued at $74,000. Panagora Asset Management Inc. purchased a new position in shares of Tenaya Therapeutics during the 2nd quarter valued at $164,000. Finally, Rhumbline Advisers boosted its holdings in Tenaya Therapeutics by 10.5% in the 2nd quarter. Rhumbline Advisers now owns 78,160 shares of the company's stock worth $242,000 after buying an additional 7,441 shares during the period. 90.54% of the stock is owned by hedge funds and other institutional investors.
Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Tenaya Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tenaya Therapeutics wasn't on the list.
While Tenaya Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.